Diabetes

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar GLP-1 drugs if they are struggling with weight. That support doesn't go for teens.

With continuous glucose monitors, students with Type 1 diabetes no longer have to visit the school nurse for a finger prick. But some parents say it falls to them to keep an eye on blood sugar levels from home or work.

After developing Type 2 diabetes and having a heart attack in his 40s, Clearwater resident Fabricio Zambrano switched to a plant-based lifestyle.

With artificial intelligence in health care on the rise, eye screenings for diabetic retinopathy are emerging as one of the first proven use cases of AI-based diagnostics in a clinical setting.

A five-year plan takes aim at higher levels of education and treatment for those not always able to connect with health services.

Adults who develop one autoimmune form of diabetes are often misdiagnosed with Type 2. Those wrong diagnoses make it harder to get the appropriate medications and technology to manage blood sugar.

Last January, Anderson Ata became the seventh person in the world to receive teplizumab, which researchers say is the first big milestone in treating diabetes since the first production of insulin over 100 years ago.

Dr. Henry Rodriguez, who is in charge of the USF Center for Diabetes and Endocrinology, said there are classic symptoms to watch out for.

Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.

Drugmakers long ceased to be the only villain of the insulin price scandal. While Lilly is cutting the list price and others may follow, will other "parties" (i.e. pharmacy benefit managers) cause the cost to increase before it hits the pharmacy counter?

Young Black adults, Mexican Americans and other Hispanic adults experienced the greatest cardiovascular risk factors, according to a study published in the Journal of the American Medical Association.

The moves announced Wednesday promise critical relief to some people with diabetes who can face annual costs of more than $1,000 for insulin they need in order to live.